NCT03255070 2024-02-01A Dose-escalation, Expansion Study of ARX788, in Advanced Solid Tumors Subjects With HER2 Expression (ACE-Pan Tumor 01)Ambrx, Inc.Phase 1 Completed106 enrolled
NCT02512237 2020-06-05A Dose-escalation Study of ARX788, IV Administered in Subjects With Advanced Cancers With HER2 ExpressionZhejiang Medicine Co., Ltd.Phase 1 Terminated9 enrolled